DE69738653T2 - Klonierung und charakterisierung von napsin, einer aspartat-protease - Google Patents
Klonierung und charakterisierung von napsin, einer aspartat-protease Download PDFInfo
- Publication number
- DE69738653T2 DE69738653T2 DE69738653T DE69738653T DE69738653T2 DE 69738653 T2 DE69738653 T2 DE 69738653T2 DE 69738653 T DE69738653 T DE 69738653T DE 69738653 T DE69738653 T DE 69738653T DE 69738653 T2 DE69738653 T2 DE 69738653T2
- Authority
- DE
- Germany
- Prior art keywords
- napsin
- antibody
- human
- enzyme
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 101000898643 Candida albicans Vacuolar aspartic protease Proteins 0.000 title description 24
- 101000898783 Candida tropicalis Candidapepsin Proteins 0.000 title description 24
- 101000898784 Cryphonectria parasitica Endothiapepsin Proteins 0.000 title description 24
- 101000933133 Rhizopus niveus Rhizopuspepsin-1 Proteins 0.000 title description 24
- 101000910082 Rhizopus niveus Rhizopuspepsin-2 Proteins 0.000 title description 24
- 101000910079 Rhizopus niveus Rhizopuspepsin-3 Proteins 0.000 title description 24
- 101000910086 Rhizopus niveus Rhizopuspepsin-4 Proteins 0.000 title description 24
- 101000910088 Rhizopus niveus Rhizopuspepsin-5 Proteins 0.000 title description 24
- 101000898773 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Saccharopepsin Proteins 0.000 title description 24
- 238000010367 cloning Methods 0.000 title description 5
- 238000012512 characterization method Methods 0.000 title description 2
- 102000004190 Enzymes Human genes 0.000 claims abstract description 27
- 108090000790 Enzymes Proteins 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 25
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 13
- 239000000975 dye Substances 0.000 claims description 3
- 210000005260 human cell Anatomy 0.000 claims description 3
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 36
- 239000002299 complementary DNA Substances 0.000 abstract description 26
- 102000004169 proteins and genes Human genes 0.000 abstract description 21
- 239000002773 nucleotide Substances 0.000 abstract description 20
- 125000003729 nucleotide group Chemical group 0.000 abstract description 20
- 210000001519 tissue Anatomy 0.000 abstract description 14
- 108090000258 Cathepsin D Proteins 0.000 abstract description 13
- 102000003908 Cathepsin D Human genes 0.000 abstract description 12
- 239000000523 sample Substances 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 11
- 102000035101 Aspartic proteases Human genes 0.000 abstract description 9
- 108091005502 Aspartic proteases Proteins 0.000 abstract description 9
- 108091005804 Peptidases Proteins 0.000 abstract description 9
- 239000004365 Protease Substances 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 238000002955 isolation Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 5
- 238000003776 cleavage reaction Methods 0.000 abstract description 3
- 230000007017 scission Effects 0.000 abstract description 3
- 108010044467 Isoenzymes Proteins 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 210000005084 renal tissue Anatomy 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 229940088598 enzyme Drugs 0.000 description 21
- 235000018102 proteins Nutrition 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 101000581940 Homo sapiens Napsin-A Proteins 0.000 description 9
- 238000012216 screening Methods 0.000 description 9
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 8
- 235000011130 ammonium sulphate Nutrition 0.000 description 8
- 102000046387 human NAPSA Human genes 0.000 description 8
- 108010091212 pepstatin Proteins 0.000 description 8
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 229950000964 pepstatin Drugs 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108010062466 Enzyme Precursors Proteins 0.000 description 4
- 102000010911 Enzyme Precursors Human genes 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108090000783 Renin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 108010044426 integrins Proteins 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940009098 aspartate Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 108010028067 procathepsin D Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000004178 Cathepsin E Human genes 0.000 description 2
- 108090000611 Cathepsin E Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000053356 human CTSD Human genes 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100166423 Mus musculus Ccdc47 gene Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 102100027343 Napsin-A Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000023011 digestive tract development Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- -1 iodoacetamido Chemical group 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3119696P | 1996-11-20 | 1996-11-20 | |
| US31196P | 1996-11-20 | ||
| US4612697P | 1997-05-09 | 1997-05-09 | |
| US46126P | 1997-05-09 | ||
| PCT/US1997/021684 WO1998022597A2 (en) | 1996-11-20 | 1997-11-20 | Cloning and characterization of napsin, an aspartic protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69738653D1 DE69738653D1 (de) | 2008-06-05 |
| DE69738653T2 true DE69738653T2 (de) | 2009-06-04 |
Family
ID=26706937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69738653T Expired - Lifetime DE69738653T2 (de) | 1996-11-20 | 1997-11-20 | Klonierung und charakterisierung von napsin, einer aspartat-protease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6225103B1 (enExample) |
| EP (1) | EP0948630B1 (enExample) |
| JP (2) | JP2001503643A (enExample) |
| AT (1) | ATE393227T1 (enExample) |
| AU (1) | AU734220B2 (enExample) |
| CA (1) | CA2271294A1 (enExample) |
| DE (1) | DE69738653T2 (enExample) |
| DK (1) | DK0948630T3 (enExample) |
| ES (1) | ES2308791T3 (enExample) |
| PT (1) | PT948630E (enExample) |
| WO (1) | WO1998022597A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0897986A3 (en) * | 1997-08-21 | 2000-07-05 | Smithkline Beecham Corporation | Aspartic proteinase 5 (ASP5) |
| US6432690B1 (en) | 1998-01-16 | 2002-08-13 | Incyte Genomics, Inc. | Human aspartic proteases |
| US7045333B1 (en) * | 1998-01-16 | 2006-05-16 | Incyte Corporation | Human protease molecules |
| US6203979B1 (en) | 1998-01-16 | 2001-03-20 | Incyte Pharmaceuticals, Inc. | Human protease molecules |
| US7160679B1 (en) | 1998-05-21 | 2007-01-09 | Diadexus, Inc. | Method of diagnosing, monitoring, and staging lung cancer |
| AU5213199A (en) * | 1998-07-16 | 2000-02-07 | Incyte Pharmaceuticals, Inc. | Human aspartic proteases |
| EP1939297A1 (en) | 1998-09-24 | 2008-07-02 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
| US7115410B1 (en) * | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| CN1390232A (zh) | 1999-02-10 | 2003-01-08 | 艾兰制药公司 | 人β分泌酶、抑制剂、其组合物和用途 |
| US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| JP2001172200A (ja) * | 1999-12-17 | 2001-06-26 | Meneki Seibutsu Kenkyusho:Kk | ヒトナプシンａに対する抗体およびこれを用いる医薬 |
| JP2003528071A (ja) | 2000-03-23 | 2003-09-24 | エラン ファーマスーティカルズ インコーポレイテッド | アルツハイマー病治療用組成物および方法 |
| AU2001267548A1 (en) * | 2000-06-26 | 2002-01-08 | Bayer Aktiengesellschaft | Regulation of human napsin-like aspartyl protease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| ATE302751T1 (de) | 2000-06-30 | 2005-09-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| EP1500663A1 (en) * | 2000-09-28 | 2005-01-26 | Eli Lilly And Company | Secreted proteins and their uses |
| US7217556B1 (en) | 2000-12-23 | 2007-05-15 | Pfizer Inc | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease |
| US7806980B2 (en) * | 2000-12-23 | 2010-10-05 | Elan Pharmaceuticals, Inc. | Method for crystallizing human beta secretase in complex with an inhibitor |
| US7601528B1 (en) | 2000-12-23 | 2009-10-13 | Elan Pharmaceuticals, Inc. | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease |
| US7524668B1 (en) | 2001-05-10 | 2009-04-28 | Elan Pharmaceuticals, Inc. | Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof |
| US7384773B1 (en) | 2001-05-10 | 2008-06-10 | Pfizer Inc | Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof |
| MXPA03011046A (es) | 2001-06-01 | 2004-06-25 | Elan Pharm Inc | Hidroxialquilaminas. |
| MXPA03011521A (es) | 2001-06-13 | 2004-03-18 | Elan Pharm Inc | Aminadioles para tratamiento de enfermedad de alzheimer. |
| MXPA04000140A (es) | 2001-06-27 | 2004-06-03 | Elan Pharm Inc | Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer. |
| BR0211118A (pt) | 2001-07-10 | 2004-10-26 | Elan Pharm Inc | Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal |
| US7053109B2 (en) | 2001-07-10 | 2006-05-30 | Pharmacia & Upjohn Company | Aminediols for the treatment of Alzheimer's disease |
| US7186539B1 (en) | 2001-08-31 | 2007-03-06 | Pharmacia & Upjohn Company | Method for refolding enzymes |
| CA2462851A1 (en) | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
| IL161881A0 (en) | 2001-11-08 | 2005-11-20 | Upjohn Co | N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| AU2003213252A1 (en) | 2002-02-21 | 2003-09-09 | Pharmacia And Upjohn Company | Modified bace |
| US7262208B2 (en) | 2002-04-30 | 2007-08-28 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of Alzheimer's disease |
| US7442537B1 (en) | 2002-05-10 | 2008-10-28 | Elan Pharmaceuticals, Inc. | Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof |
| AU2003268023A1 (en) * | 2002-07-23 | 2004-02-09 | Incyte Corporation | Protein modification and maintenance molecules |
| BR0316629A (pt) | 2002-11-27 | 2005-10-11 | Elan Pharm Inc | Uréias e carbamatos substituìdos |
| CA2523232A1 (en) | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | (hetero) arylamide 2-hydroxy-3-diaminoalkanes for use in the treatment of alzheimer's disease |
| JP4739192B2 (ja) | 2003-05-02 | 2011-08-03 | イーラン ファーマスーティカルズ、インコーポレイテッド | Ｂａｃｅのグリコシル化変異体 |
| WO2005044977A2 (en) * | 2003-06-25 | 2005-05-19 | Diadexus, Inc. | Compositions, splice variants and methods relating to lung specific genes and proteins |
| CA2558034A1 (en) | 2004-03-09 | 2005-09-22 | Elan Pharmaceuticals, Inc. | Substituted hydroxyethylamine aspartyl protease inhibitors |
| US20070292346A1 (en) * | 2004-03-25 | 2007-12-20 | Rong Fan | Lng105 Antibody Composition and Methods of Use, and Use of Lng105 to Assess Lung Cancer Risk |
| CA2573138A1 (en) | 2004-07-09 | 2006-01-26 | Elan Pharmaceuticals Inc. | Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors |
| WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
| JP5450407B2 (ja) | 2007-07-06 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107250A (en) * | 1993-10-12 | 2001-08-08 | Yeda Res & Dev | Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins |
| GB9618966D0 (en) * | 1996-09-11 | 1996-10-23 | Smithkline Beecham Plc | Novel compounds |
| US5776759A (en) * | 1996-09-26 | 1998-07-07 | Incyte Pharmaceuticals, Inc. | Two novel human cathepsin proteins |
-
1997
- 1997-11-20 DK DK97948546T patent/DK0948630T3/da active
- 1997-11-20 WO PCT/US1997/021684 patent/WO1998022597A2/en not_active Ceased
- 1997-11-20 DE DE69738653T patent/DE69738653T2/de not_active Expired - Lifetime
- 1997-11-20 CA CA002271294A patent/CA2271294A1/en not_active Abandoned
- 1997-11-20 US US08/974,691 patent/US6225103B1/en not_active Expired - Lifetime
- 1997-11-20 EP EP97948546A patent/EP0948630B1/en not_active Expired - Lifetime
- 1997-11-20 ES ES97948546T patent/ES2308791T3/es not_active Expired - Lifetime
- 1997-11-20 JP JP52398598A patent/JP2001503643A/ja not_active Withdrawn
- 1997-11-20 AU AU54592/98A patent/AU734220B2/en not_active Ceased
- 1997-11-20 AT AT97948546T patent/ATE393227T1/de active
- 1997-11-20 PT PT97948546T patent/PT948630E/pt unknown
-
2007
- 2007-11-15 JP JP2007297327A patent/JP2008118996A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU5459298A (en) | 1998-06-10 |
| CA2271294A1 (en) | 1998-05-28 |
| AU734220B2 (en) | 2001-06-07 |
| JP2001503643A (ja) | 2001-03-21 |
| DK0948630T3 (da) | 2008-08-11 |
| EP0948630A2 (en) | 1999-10-13 |
| DE69738653D1 (de) | 2008-06-05 |
| US6225103B1 (en) | 2001-05-01 |
| WO1998022597A2 (en) | 1998-05-28 |
| ATE393227T1 (de) | 2008-05-15 |
| WO1998022597A3 (en) | 1998-07-09 |
| JP2008118996A (ja) | 2008-05-29 |
| PT948630E (pt) | 2008-06-11 |
| EP0948630B1 (en) | 2008-04-23 |
| ES2308791T3 (es) | 2008-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69738653T2 (de) | Klonierung und charakterisierung von napsin, einer aspartat-protease | |
| WO1998022597A9 (en) | Cloning and characterization of napsin, an aspartic protease | |
| DE69914309T2 (de) | Tadg15: eine extrazelluläre serinprotease überexprimiert in brust- und eierstock-karzinomen | |
| WO1995030758A9 (en) | Recombinant hk2 polypeptide | |
| JPH10500294A (ja) | 組換え型ｈｋ２ポリペプチド | |
| DE68922297T2 (de) | Für das menschliche angiotension-umformungsenzym (ace) kodierende nukleinsäure und ihre anwendungen, insbesondere zur in-vitro-diagnose von bluthochdruck. | |
| WO1995025171A2 (de) | Dna-sequenzen für matrix-metallproteasen, ihre herstellung und verwendung | |
| DE69720335T2 (de) | Recombinante Fructosyl-Aminosäure-Oxidase | |
| DE69223802T2 (de) | Heparinase Gen von Flavobacterium Heparinum | |
| US5821067A (en) | Mammalian methadone-specific opioid receptor and uses in binding assays | |
| EP0936270A2 (de) | Serinprotease aus der Prostata | |
| CN117756930A (zh) | 针对猴痘病毒a35r蛋白的抗体及其相关产品和用途 | |
| DE3787112T2 (de) | Menschliche Pankreaselastase I. | |
| DE69433915T2 (de) | MDC-Proteine und dafür kodierende DNS | |
| US5883241A (en) | DNA sequences coding for a human metalloproteinase and variants thereof | |
| DE69216600T2 (de) | Synthetisches CDw52(CAMPATH-1) Peptidantigen | |
| DE69836482T2 (de) | Menschliches recq4 gen, das für eine helikase kodiert | |
| DE69034060T2 (de) | Nukleinsäure, die für das menschliche testikulare angiotensin konvertierende enzym (ace) kodiert, und seine anwendungen, insbesondere für die in vitro-detektion des enzyms im organismus | |
| DE60018279T2 (de) | Diagnostische verwendungen von gegen acetylcholinesterase oder deren c-terminale peptide gerichteten antikörpern | |
| DE69412466T2 (de) | Neue metalloprotease und kodierende dna dafür | |
| JPH05508551A (ja) | ガンマーカルボキシラーゼおよび使用の方法 | |
| US5731192A (en) | Collagen COL4A6: gene, protein and method of detecting collagen deficiency | |
| JP2001503991A (ja) | 転移性前立腺癌の検出方法 | |
| DE60015559T2 (de) | Sentrin-spezifische menschliche protease senp1 | |
| EP0422217B1 (en) | Human recombinant placental ribonuclease inhibitor and method of production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |